Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quji Tongluo
- Development stage
- Phase 1
- Lead developer
- Eye Hospital, China Academy of Chinese Medical Sciences
- Administration
- Oral
01
Overview
Quji Tongluo is a Traditional Chinese Medicine (TCM) formula developed by the Eye Hospital of the Chinese Academy of Chinese Medical Sciences. It is primarily used for the treatment of retinal vascular diseases, specifically macular edema secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). The formula is designed based on the TCM principles of removing blood stasis ("Quji") and dredging the collaterals ("Tongluo") to improve retinal circulation and reduce edema. It is often studied as an adjunctive oral therapy alongside anti-VEGF agents like ranibizumab to enhance therapeutic outcomes in patients with retinal vein occlusion.
- Other names
- Quji Tongluo decoctionQuji Tongluo Granules
02
Targets
Beyond the preview
Go deeper on Quji Tongluo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quji Tongluo.